Abstract
We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.
Translated title of the contribution | Efficacy and safety of Levetiracetam as add-on therapy in patients with refractory partial epilepsy: A long-term, open-label, prospective study |
---|---|
Original language | Italian |
Pages (from-to) | 195-197 |
Number of pages | 3 |
Journal | Bollettino - Lega Italiana contro l'Epilessia |
Issue number | 125-126 |
Publication status | Published - Jul 2004 |
ASJC Scopus subject areas
- Clinical Neurology